Text/Yangcheng Evening News all-media reporter Zhang Hua
Photo/Visual China
The reporter learned from the State Drug Administration that recently, the dual-targeted combination therapy drugs darafenib mesylate capsules and trimetinib tablets were approved for the treatment of BRAF V600 mutation-positive metastatic non-small cell lung cancer (NSCLC).
Professor Zhang Li, director of the Department of Oncology and chief expert of lung cancer at the Cancer Prevention and Control Center of Sun Yat-sen University, pointed out that "the approval of the DALAFEN combined with trimetinib for the treatment of BRAF mutant lung cancer is an exciting thing, making BRAF V600 another advanced NSCLC targetable gene mutation after EGFR, ALK and ROS1, which is another important milestone in the field of targeted therapy for lung cancer." ”
After a mutation in a lung cancer gene, targeted drugs benefit patients
Lung cancer is the highest malignant tumor in Terms of Morbidity and Mortality in China, of which non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer.
For early cancer, the tumor is limited to the locality, and the doctor can solve the tumor relatively thoroughly through surgical resection (precision strike). But tumors differ from other diseases in that the spread of tumor cells can produce new tumors in other sites, forming metastatic cancers. This advanced cancer is usually considered to be of little value to surgery, so it requires a system of medication (extensive combat).
So, lung cancer does not have genetic mutations, is this good or bad? The answer to the question will obviously not be as simple as "good" or "bad". Since lung cancer targeting has ushered in a new era of precision therapy, more and more targets have been discovered, and the targeted new drugs corresponding to these targets have also brought more and better benefits to patients' treatment.
Rare targeted also has new drug treatments
Lung cancer, especially non-small cell lung cancer, is the most complete, the most diverse and the fastest growing of targeted drugs among all cancers.
Unlike common targets such as EGFR and ALK, rare targets with low incidence such as BRAF, NTRK1, RET, etc. have not had a variety of treatments, but they have ushered in new progress. The reporter learned from the State Drug Administration that recently, the dual-targeted combination therapy drugs darafenib mesylate capsules and trimetinib tablets were approved for the treatment of BRAF V600 mutation-positive metastatic non-small cell lung cancer (NSCLC).
"BRAF mutations are rare driver genes for advanced NSCLC, and patients with BRAF V600 mutations have a poor prognosis and short overall survival, and the clinical benefits of chemotherapy and immunotherapy are not ideal at present," Zhang said. This approval gives us another effective treatment for BRAF mutant lung cancer, and also opens up a new direction for targeted therapy in adjuvant therapy for NSCLC patients. In addition, experts also pointed out that the way oral administration also makes patients more convenient and more compliant. (For more news, please pay attention to Yangcheng Pie pai.ycwb.com)
Source | Yangcheng Evening News Yangcheng Pie
Editor-in-charge | Wang Moyi